Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves Azstarys to treat attention deficit hyperactivity disorder – Kem Pharma Inc

Written by | 15 Mar 2021 | Psychiatry

KemPharm, Inc. has announced that the FDA has approved the New Drug Application for Azstarys (formerly referred to as KP 415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.

Azstarys consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH. Corium, Inc. a portfolio company of Gurnet Point Capital (GPC), will lead the commercialization of Azstarys per the definitive collaboration and license agreement (the “License Agreement”) between KemPharm and an affiliate of GPC. Corium expects to make Azstarys commercially available in the U.S. as early as the second half of 2021.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.